Philadelphia, January 3, 2019- Psychiatric disorders share common alterations of functional connectivity between three core brain networks involved in cognition, according to a meta-analysis published in Biological Psychiatry. The network alterations were localized in brain regions underlying general cognitive performance. The study suggests that the alterations in these networks contribute to the cognitive dysfunction present in multiple psychiatric disorders.
The alterations in functional connectivity, which emerged from a meta-analysis of 242 functional brain imaging studies in people with a variety of psychiatric disorders, were found in the three large-scale networks considered to be particularly important for complex cognition—the default mode network; frontoparietal network; and the salience network. Further, analysis of 363 structural brain imaging studies revealed reduced gray matter that was confined to the altered networks, tightly linking structural and functional alterations.
Importantly, the study provides the first evidence from a meta-analysis of common functional connectivity alterations in neurocognitive networks across psychiatric disorders. “This new knowledge calls for studying brain-based diagnostic biomarkers of psychiatric disorders that are beyond traditional diagnostic boundaries,” said senior author Yong He, PhD, Beijing Normal University, China.
Although psychiatric illnesses are considered to be distinct disorders, cognitive dysfunction appears in most of them. This overlap of symptoms across psychiatric disorders has been a major challenge to precisely categorize patients. Although enormous progress has been made in characterizing the neural correlates of diagnoses and symptoms over the past 25 years, neuroimaging biomarkers have yet to contribute to the psychiatric diagnostic process.
“Dr. He and colleagues provide an important clue as to why neuroimaging diagnostic biomarkers have made limited progress,” said John Krystal, MD, Editor of Biological Psychiatry. “This finding pushes us to rethink the potential role of neuroimaging in the diagnostic process.”
The shared neurocognitive network alterations suggest that neuroimaging may be providing a measure of symptom-related pathology not directly related to the disease process. This could pose a problem, as the study of psychiatric disorders—which are defined by collections of symptoms—is primarily limited to the study of behaviors. It is possible that disease-specific elements of biology exist, but the similarity between disorders in this study indicate that greater efforts may be needed to adjust for common elements of pathology in the search for “disease-specific” biomarkers.
###
Notes for editors
The article is "Common Dysfunction of Large-Scale Neurocognitive Networks across Psychiatric Disorders," by Zhiqiang Sha, Tor Wager, Andrea Mechelli, and Yong He (https://doi.org/10.1016/j.biopsych.2018.11.011). It appears in Biological Psychiatry, published by Elsevier.
Copies of this paper are available to credentialed journalists upon request; please contact Rhiannon Bugno at Biol.Psych@sobp.org or +1 214 648 0880. Journalists wishing to interview the authors may contact Yong He at yong.he@bnu.edu.cn or +86 8 5880 2036.
The authors’ affiliations and disclosures of financial and conflicts of interests are available in the article.
John H. Krystal, MD, is Chairman of the Department of Psychiatry at the Yale University School of Medicine, Chief of Psychiatry at Yale-New Haven Hospital, and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here.
About Biological Psychiatry
Biological Psychiatry is the official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.
The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.
Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 6th out of 142 Psychiatry titles and 9th out of 261 Neurosciences titles in the Journal Citations Reports® published by Clarivate Analytics. The 2017 Impact Factor score for Biological Psychiatry is 11.982. http://www.sobp.org/journal
About Elsevier Elsevier is a global information analytics business that helps institutions and professionals advance healthcare, open science and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support and professional education, including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, more than 38,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. http://www.elsevier.com
Media contact
Rhiannon Bugno, Editorial Office
Biological Psychiatry
+1 214 648 0880
Biol.Psych@sobp.org
Journal
Biological Psychiatry